SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ:BTAI) investors who suffered substantial losses to submit your losses now.
Class Period: Dec. 15, 2021 – June 28, 2023
Lead Plaintiff Deadline: Sept. 5, 2023
Visit: www.hbsslaw.com/investor-fraud/BTAI
Contact An Attorney Now: BTAI@hbsslaw.com
844-916-0895
BioXcel Therapeutics, Inc. (BTAI) Securities Fraud Class Action:
The litigation focuses on BioXcel's statements and omissions regarding its TRANQUILITY II study evaluating its Alzheimer candidate drug BXCL501.
The complaint alleges Defendants failed to disclose to investors that: (1) BioXcel lacked adequate internal controls over protocol adherence and data integrity; (2) its principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) the principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) the principal investigator fabricated ...